I might make EXEL shares a "2% of my portfolio" position next week. That would probably make it the 4th largest, so maybe it is a good idea to wrote a post about Exelixis, mostly to convince myself that adding to my position is a good idea.
zzlangerhans wrote this.
Exelixis (EXEL) - market cap 531M, share price 4.89. Cash 153M, debt 76M, burn 25-45M. The most heavily green-thumbed baby biotech in CAPS is also one of the most frustrating. Exelixis has been around more than ten years and the share price has been below 5 for about 5% of that time. I won't get into the extremely complex and wide pipeline, but suffice it to say that a lot of trials are going on and positive or negative catalysts could occur at any time. Dilution is always a possibility. However, nothing about Exelixis's current position indicates that they should be significantly undervalued compared to their historical valuation. Green-thumbers are a virtual CAPS All-Star team, including Vanamonde, Eldrehad, NTMF, SpecBear(!), and Portefeuille although admittedly most of those picks are ancient and deeply under water. I see this as a GBMB buy under 4.5.
and this in comment #10 to that post.
3000 shares bought yesterday at 3.69. Yum.